Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) were up 2.5% during mid-day trading on Friday . The stock traded as high as $4.62 and last traded at $4.59, with a volume of 691,195 shares trading hands. The stock had previously closed at $4.48.

Several analysts have recently issued reports on CLDX shares. Jefferies Group reiterated a “hold” rating and issued a $4.00 price objective on shares of Celldex Therapeutics in a research note on Friday, May 6th. Roth Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Cowen and Company reiterated an “outperform” rating and issued a $12.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, June 7th. Finally, Wedbush restated a “neutral” rating and issued a $3.00 price target on shares of Celldex Therapeutics in a research note on Friday, May 6th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $14.11.

The stock’s market cap is $463.97 million. The stock has a 50-day moving average of $4.47 and a 200 day moving average of $5.96.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.35). The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $1.06 million. The firm’s quarterly revenue was up 160.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.33) earnings per share. On average, equities research analysts forecast that Celldex Therapeutics Inc. will post ($1.36) EPS for the current year.

A number of hedge funds have made changes to their positions in CLDX. Columbia Wanger Asset Management LLC boosted its stake in shares of Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares during the period. ProShare Advisors LLC boosted its stake in shares of Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares during the period. TSP Capital Management Group LLC boosted its stake in shares of Celldex Therapeutics by 0.8% in the fourth quarter. TSP Capital Management Group LLC now owns 831,648 shares of the biopharmaceutical company’s stock worth $13,040,000 after buying an additional 6,967 shares during the period. Bedell Frazier Investment Counseling LLC boosted its stake in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the period.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.